Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPly®AM [Yahoo! Finance]
Organogenesis Holdings Inc. - Class A (ORGO)
Last organogenesis holdings inc. - class a earnings: 3/9 04:05 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
Results strengthen existing clinical evidence supporting future coverage CANTON, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced the completion of a randomized controlled trial (RCT) evaluating PuraPly®AM plus standard of care (SOC) versus SOC alone in the management of non-healing diabetic foot ulcers (DFUs). The prospective, multi-center, randomized controlled trial of 170 patients evaluated the safety and efficacy of PuraPly® AM plus SOC. The trial achieved its primary endpoint, demonstrating statistically significant wound closure at 12 weeks, compared to SOC alone (p “We are pleased to report primary endpoint achievement in this important study underscoring the clinical efficacy of PuraPly®AM in the management of non-healing DFUs
Show less
Read more
Impact Snapshot
Event Time:
ORGO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ORGO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ORGO alerts
High impacting Organogenesis Holdings Inc. - Class A news events
Weekly update
A roundup of the hottest topics
ORGO
News
- Organogenesis Holdings, Inc. Investigated by the Portnoy Law FirmGlobeNewswire
- Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPly®AMGlobeNewswire
- Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis PainGlobeNewswire
- Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026GlobeNewswire
- Organogenesis (ORGO) had its "buy" rating reaffirmed by BTIG Research. They now have a $8.00 price target on the stock.MarketBeat
ORGO
Earnings
- 5/8/25 - Miss
ORGO
Sec Filings
- 3/11/26 - Form 4
- 3/11/26 - Form 4
- 3/3/26 - Form 4
- ORGO's page on the SEC website